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Accepted 8 February 20085-Fluoro-2′-deoxyuridine (FUdR), a potent anticancer agent, exerts its effects by inhibiting thymidylate
synthase, an essential machinery for DNA synthesis in cell proliferation. Also, cell death is caused by FUdR,
primarily due to an imbalance in the nucleotide pool resulting from this enzyme inhibition. We have
investigated the cancer cell death induced by FUdR, focusing on its molecular mechanisms. Using mouse
mammary tumor FM3A cell lines, the original clone F28-7 and its variant F28-7-A cells, we previously reported
an interesting observation that FUdR induces a necrotic morphology in F28-7, but induces, in contrast, an
apoptotic morphology in F28-7-A cells. In the present study, to understand the molecular mechanisms
underlying these differential cell deaths, i.e., necrosis and apoptosis, we investigated the gene expression
changes occurring in these processes. Using the cDNA microarray technology, we found 215 genes being
expressed differentially in the necrosis and apoptosis. Further analysis revealed differences between these cell
lines in terms of the expressions of both a cluster of heat shock protein (HSP)-related genes and a cluster of
apoptosis-related genes. Notably, inhibition of HSP90 in F28-7 cells caused a shift from the FUdR-induced
necrosis into apoptosis. These ﬁndings are expected to lead to a better understanding of this anticancer drug
FUdR for its molecular mechanisms and also of the general biological issue, necrosis and apoptosis.







5-Fluoro-2′-deoxyuridine (FUdR), a potent anticancer agent, exerts
its effects by inhibiting thymidylate synthase, an essential machinery
for DNA synthesis in cell proliferation [1–6]. 5-Fluoro-2′-deoxyuridine
5′-monophosphate has been shown to form a covalent complex with
thymidylate synthase in the presence of 5,10-methylenetetrahydrofo-
late [3–6]. The inhibition of thymidylate synthesis causes an imbalance
in the deoxyribonucleoside triphosphate (dNTP) pool, leading to cell
death [7].
Although cell death is, on one hand, associated with normal cellular
development and homeostasis, it is associatedwith various pathological
processes. Two general pathways for cell death have been deﬁned,
apoptosis and necrosis. Depending on the cell type, cellular context, or
stimulus, a cell may die by apoptosis or by necrosis [8]. Apoptosis is
morphologically characterized by membrane blebbing, shrinking of the
cell and its organelles, and oligonucleosomal degradation of DNA, follo-
wed by disintegration of the cell; and the resulting fragments are
phagocytosed by neighboring cells [9,10]. In contrast, necrosis is charac-
terized by swelling of the cell and the organelles, and the disruption ofya).
l rights reserved.the cell membrane, resulting in cell lysis. Necrosis is often accompanied
by inﬂammation due to release of the cellular components [8,11]. The
molecular mechanisms of apoptosis have been well studied, whereas
less is known about the processes involved in necrosis. In recent years,
research on necrosis and apoptosis has attracted much attention, be-
cause disruption of cell death pathways can lead to various diseases.
We have investigated themolecularmechanisms regulating necrosis
and apoptosis that occur on treatment ofmousemammary tumor FM3A
cells with FUdR, using the original clone F28-7 and its variant F28-7-A
cells. Previously, we reported that the treatment can induce in F28-7
cells a breakdown of DNA into chromosome-sized fragments leading to
necrosis; on the other hand, it can induce in F28-7-A a more extensive
DNA cleavage into oligonucleosome-sized fragments and subsequent
development of apoptosis [12]. These observations prompted us to
further investigate the cytotoxic action of FUdR, with the hope to better
understand the molecular mechanisms of the activities of this drug and
also to obtain clues for the elucidation of general biological phenomena,
necrosis and apoptosis. Recent development of genomics has now en-
abled us for the ﬁrst time analyze the gene expression proﬁles of ne-
crosis induced by FUdR in F28-7 cells and those of apoptosis in F28-7-A
cells. Using cDNA microarray technology, the study revealed 215 genes
that were differentially expressed in the FUdR-induced necrosis and
apoptosis. Of particular interest were changes in the expression pattern
Fig. 1. Gene expression proﬁles in F28-7 and F28-7-A cells treated with FUdR. RNA isolated
fromFM3Acells F28-7 and F28-7-A that had been treatedwith 1 μMFUdR for 0 (no drug, no
incubation), 4, 8, or 16 h was subjected to microarray analysis using GeneChip Mouse
ExpressionArray430A (Affymetrix). For each cell line, three independentexperimentswere
performed at individual treatment times. Gene expression data were analyzed using Array
Assist ver. 5.2. software (Stratagene). For statistical analysis, 411 probe sets were selected as
differentially expressed genes in apoptosis and necrosis after treatment with FUdR, using
ANOVAwith the P values set at smaller than 0.001. Then, the selected genes were subjected
to hierarchical clustering. Numbers 1–5 indicate ﬁve different clusters identiﬁed by
hierarchical clustering. The yellow and blue boxes indicate genes of cluster 1 and cluster 3,
respectively. Higher signal values are shown in red, and lower signal values in green.
10 A. Sato et al. / Genomics 92 (2008) 9–17of a group of apoptosis-related genes, including BCL-2 family members
and caspases, a family of cysteine proteases. Another interesting group
was the heat shock protein (HSP) family and related genes, including
DnaJ (Hsp40) homolog, subfamily B, member 4 (Dnajb4), heat shock
protein 110 (Hsp110), and AHA1, activator of heat shock protein ATPase
homolog 1 (Ahsa1). An immunoﬂuorescence study revealed that FUdR
can induce release of cytochrome c frommitochondria to the cytoplasm
andnucleus in F28-7-A cells, but not in F28-7 cells. However, a combined
treatment with FUdR and geldanamycin (GA), the latter being an inhi-
bitor toward a molecular chaperone HSP90, caused DNA cleavage into
oligonucleosome-size fragments, an apoptotic morphology, followed by
release of cytochrome c frommitochondria to cytoplasm and to nucleus
in F28-7 cells. These ﬁndings suggest that HSP90 can play an important
role in the regulation of cell death. It should be noted that the involve-
ment of HSP90 has been recognized as being associatedwith various cell
activities, e.g., cell cycle control, cell development, and cell death [13–19].
Results
Gene expression proﬁles in FUdR-induced necrosis and apoptosis
To proﬁle the changes in the pattern of gene expression in FUdR-
induced necrosis and apoptosis, F28-7 and F28-7-A cells were treated
with 1 μM FUdR for 0 (no drug, no incubation), 4, 8, and 16 h. The
treatment with FUdR caused induction of necrosis in F28-7 cells and
apoptosis in F28-7-A cells. In agreement with our previous report [12],
both F28-7 and F28-7-A exhibited a very similar cell morphology in the
absence of FUdR (both at 0 time and at 16 h; data not shown). The
treatment periods we chose for the analysis of this drug action were
based on our previous studies [12]: namely, at 4 h no decrease in
viability; at 8 h still no decrease in viability; at 16 h signiﬁcant decrease
notable, about 60% with F28-7, and about 80% with F28-7-A. At each
time period, cells were collected and the total RNA was isolated and
reverse-transcribed, and the cDNAs produced were subjected to micro-
array analysis. For both of these cells at each time of the treatment, three
independent analyses were performed with the GeneChip Mouse Ex-
pression Array 430A, which contains 22,600 probe sets and can be used
to analyze the expression level of ∼14,000 known mouse genes.
For statistical analysis, the one-way analysis of variance (ANOVA)
was performed on all the genes of the probe sets, and a change in gene
expressionwas considered signiﬁcant if the P valuewas less than 0.001
after application of the Bonferroni correction. Thus, 411 probe sets
representing 371 genes were identiﬁed as differentially expressed in
F28-7 and F28-7-A cells at each time period of the treatment (including
the 0 h). The selected genes were then classiﬁed by hierarchical clus-
tering according to the similarity in their expression proﬁle, and as a
result ﬁve clusters were generated as shown in Fig. 1. As can be seen in
this ﬁgure, the gene expression-change patterns differed considerably
between F28-7 and F28-7-A during the course of the treatment. These
changes obviously deserved extensive investigation.
A remarkable observation was that in the untreated stage (the 0 h
samples),113genes aredifferentiallyexpressed (more than+/−1.5-fold) in
F28-7 and F28-7-A cells. These differentially expressed genes were
grouped by their function, apoptosis, cytoskeleton organization, signal
transduction, transcription, and transport. In these 113 genes, 29 genes
were expressed with a large difference (more than 10-fold). They are
listed in SupplementaryData (SupplementaryTable1).On theotherhand,
the expression of 18 genes changed dynamically (more than 10-fold)
during the FUdR treatment in either F28-7 or F28-7-A cells. Among them,
the changes in 3 genes had a similar pattern in F28-7 and F28-7-A cells.
Therefore, there were 15 genes that had a greatly different manner of
change between the necrosis and apoptosis. We suspect that these genes
include those that determine the death pattern. These 15 genes are listed
in Supplementary Data (Supplementary Table 2).
Gene clusters 1 and 3 are those differentially expressed in necrosis
and apoptosis in the FUdR treatment. Cluster 3 contained genes withupregulated expressions and cluster 1 those with downregulated ex-
pressions in the induced necrosis as compared to the apoptosis. Genes
in clusters 2, 4, and 5 were expressed similarly in both types of cell
death. These gene lists are provided as Supplementary Data (Supple-
mentary Tables 3 to 5).
Differentially expressed genes in necrosis and apoptosis were grou-
ped by their functions, and catalogued in Table 1 (cluster 3) and Table 2
(cluster 1). These functions include apoptosis, cell adhesion, cell cycle,
cell growth, cell motility, cell proliferation and differentiation, develop-
ment, DNA repair and replication, chromatin modiﬁcation, cytoskeleton
organization, keratinisation, plasmamembrane repair, immune response,
redox homeostasis, metabolism, mRNA processing, ATP biosynthesis,
phospholipid biosynthesis, fatty acid biosynthesis, protein synthesis and
folding, protein modiﬁcation and degradation, signal transduction, trans-
cription, and transport (Tables 1 and 2). These differentially expressed
genes are those functioning at various stages of important biological
processes. In particular, genes corresponding to a number of apoptosis
regulatorswere shown to exhibit the differential expressions. These genes
included B-cell leukemia/lymphoma 10 (Bcl10), BH3 interacting domain
death agonist (Bid), caspase-1 (Casp1), death-associated protein (Dap),
Table 1
Functional categorization of upregulated genes in necrosis (total: 104 genes)
GenBank Gene title
Apoptosis
BG071931 calcium/calmodulin-dependent protein kinase ID (Camk1d)
NM_130859.1 caspase recruitment domain family, member 10 (Card10)
AF047838.1 chloride channel calcium activated 1 (Clca1)
BC021786.1 integral membrane protein 2B (Itm2b)
NM_011111.1 serine (or cysteine) peptidase inhibitor, clade B,member 2 (Serpinb2)
Cell adhesion
BC005718.1 claudin 6 (Cldn6)
BB132473 L1 cell adhesion molecule (L1cam)
NM_011345.1 selectin, endothelial cell (Sele)
Cell cycle
AV126179 centrosomal protein 55 (Cep55)
Cell growth
BC001999.1 epithelial membrane protein 3 (Emp3)
X96585.1 nephroblastoma overexpressed gene (Nov)
Cell motility
AK017725.1 tropomodulin 3 (Tomod3)
Development
NM_033603.1 amnionless (Amn)
AK003744.1 cystatin E/M (Cst6)
D85028.2 sema domain, immunoglobulin domain (Ig), basic domain,
secreted, (semaphorin) 3A (Sema3a)
NM_013657.1 sema domain, immunoglobulin domain (Ig), basic domain, secreted,
(semaphorin) 3C (Sema3c)
DNA repair and DNA replication
NM_007948.1 excision repair cross-complementing rodent repair deﬁciency,
complementation group 1 (Ercc1)
BC002257.1 RIKEN cDNA 2610305J24 gene (2610305J24Rik)
NM_020296.1 RNA binding motif, single stranded interacting protein 1 (Rbms1)
Chromatin modiﬁcation
NM_008197.1 H1 histone family, member 0 (HIf0)
NM_011061.1 peptidyl arginine deiminase, type IV (Padi4)
Cytoskeleton organization
M21836.1 keratin 8 (Krt8)
NM_008471.1 keratin 19 (Krt19)






BC019961.1 chemokine (C-X-C motif) ligand 16 (Cxcl16)
NM_010406.1 hemolytic complement (Hc)
Redox homeostasis
NM_029571.1 KTI12 homolog, chromatin associated (S. cerevisiae) (Kti12)
Metabolism
NM_019811.1 acyl-CoA synthetase short-chain family member 2(Acss2)
BC024934.1 aspartoacylase (aminoacylase) 2 (Aspa)
NM_013847.1 glycine C-acetyltransferase (Gcat)
AA792094 glutamate oxaloacetate transaminase 1, soluble(Got1)
NM_008182.1 glutathione S-transferase, alpha 1 (Ya), alpha 2 (Yc2) (Gsta2)
C78422 coenzyme Q3 homolog, methyltransferase (yeast) (Coq3)
AK003232.1 carbonyl reductase 3 (Cbr3)
BB546344 hydroxysteroid (17-beta) dehydrogenase 11 (Hsd17b11)
NM_009214.1 spermine synthase (Sms)
mRNA processing
BG972112 RIKEN cDNA 5730453I16 gene (5730453I16Rik)
ATP biosynthesis
BG794445 ATP synthase, H+ transporting, mitochondrial F0 complex, subunit f,
isoform 2 (Atp5j2)




NM_023627.1 myo-inositol 1-phosphate synthase A1 (Isyna1)
Fatty acid biosynthesis
BB430611 fatty acid desaturase 2 (Fads2)
Protein biosynthesis
NM_025936.1 arginyl-tRNA synthetase (Rars)
AF321126.1 eukaryotic translation elongation factor 1 gamma (Eef1g)
BC024463.1 eukaryotic translation initiation factor 3, subunit 6 interacting protein
(Eif3s6ip)
BI104847 eukaryotic translation initiation factor 5 (Eif5)
NM_007990.1 Finkel-Biskis-Reilly murine sarcoma virus(FBR-MuSV) ubiquitously




BI499717 heat shock protein 110 (Hsp110)
Protein modiﬁcation
NM_018784.1 ST3 beta-galactoside alpha-2,3-sialyltransferase 6 (St3gal6)
NM_031386.1 testis expressed gene 14 (Tex14)
AV171029 ubiquilin 2 (Ubqln2)
Protein degradation
NM_008906.1 cathepsin A (Ctsa)
NM_133712.1 kallikrein related-peptidase 10 (Klk10)
BB250811 procollagen C-endopeptidase enhancer protein (Pcolce)
AF334269.1 WAP four-disulﬁde core domain 2 (Wfdc2)
Signal transduction
BE570050 AHNAK nucleoprotein (desmoyokin) (Ahnak)
AK008203.1 BAI1-associated protein 2-like 1 (Baiap2l1)
AV375176 centaurin, delta 1 (Centd1)
NM_007974.1 coagulation factor II (thrombin) receptor-like 1 (F2rl1)
BB251922 cyclic nucleotide phosphodiesterase 1 (Cnp1)
BB324823 latent transforming growth factor beta binding protein 3 (Ltbp3)
NM_008639.1 melatonin receptor 1A (Mtnr1a)
BC024684.1 mitogen-activated protein kinase 6 (Mapk6)
BC011193.1 prostaglandin E receptor 4 (subtype EP4) (Ptger4)
Transcription
BC019946.1 activating transcription factor 3 (Atf3)
BC006628.1 centromere protein B (Cenpb)
NM_007913.1 early growth response 1 (Egr1)
AB031037.1 eomesodermin homolog (Xenopus laevis) (Eomes)
NM_008046.1 follistatin (Fst)
NM_010235.1 fos-like antigen 1 (Fosl1)
NM_016861.1 PDZ and LIM domain 1 (elﬁn) (Pdlim1)
AU019880 Predicted gene, EG668701 (EG668701)
Transport
AK005223.1 adaptor-related protein complex 1, sigma 2 subunit (Ap1s2)
BC027319.1 ATPase, Na+/K+ transporting, beta 1 polypeptide (Atp1b1)
NM_025911.1 coiled-coil domain containing 91 (Ccdc91)
BC006732.1 cytochrome b-561 (Cyb561)
AV007132 frataxin (Fxn)
BC025550.1 gamma-aminobutyric acid (GABA-A) receptor ,pi (Gabrp)
BC024375.1 growth hormone receptor (Ghr)
NM_007515.1 solute carrier family 7 (cationic amino acid transporter, y+ system)
member 3 (Slc7a3)
AK004616.1 solute carrier organic anion transporter family, member 2a1
(Slco2a1)
Unknown
AK008203.1 BAI1-associated protein 2-like 1 (Baiap2l1)
BB223872 Bernardinelli-Seip congenital lipodystrophy 2 homolog (human)
(Bscl2)
BC027558.1 bolA-like 1 (E. coli) (Bola1)
NM_007594.1 calumenin (Calu)
BC018472.1 COBW domain containing 1 (Cbwd1)
NM_133930.1 cysteine-rich with EGF-like domains 1 (Creld1)
BG794917 expressed sequence AI462493 (AI462493)
AK013203.1 ﬁbronectin type III domain containing 4 (Fndc4)
(continued on next page)
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Table 2
Functional categorization of downregulated genes in necrosis (total: 111 genes)
GenBank Gene title
Apoptosis
NM_009740.1 B-cell leukemia/lymphoma 10 (Bcl10)
NM_007544.1 BH3 interacting domain death agonist (Bid)
BC008152.1 caspase 1 (Casp1)
BC024876.1 death-associated protein (Dap)
BB172698 glutaredoxin 2 (thioltransferase) (Glrx2)
BC011507.1 lectin, galactose binding, soluble 7 (Lgals7)
Cell adhesion
NM_010581.1 CD47 antigen (Cd47)
NM_010494.1 intercellular adhesion molecule 2 (Icam2)
AA516617 plakophilin 2 (Pkp2)
AV026492 thrombospondin 1 (Thbs1)
Cell cycle
BC027022.1 RIKEN cDNA 1810009O10 gene (1810009O10Rik)
AB040489.1 RIKEN cDNA 2610204L23 gene (2610204L23Rik)
Cell motility
BC002136.1 coronin, actin binding protein 1A (Coro1a)
Cell proliferation and differentiation
NM_010216.1 c-fos induced growth factor (Figf)
BB000455 granulin (Grn)
Development
BC003916.1 RIKEN cDNA 0610007P06 gene (0610007P06Rik)
NM_011340.1 serine (or cysteine) peptidase inhibitor, clade F, member 1 (Serpinf1)
DNA repair and DNA replication
NM_009687.1 apurinic/apyrimidinic endonuclease 1 (Apex1)
AF072521.1 poly (ADP-ribose) polymerase family, member 2 (Parp2)
AK010619.1 prohibitin (Phb)
NM_011232.1 RAD1 homolog (S. pombe) (Rad1)
Chromatin modiﬁcation
U97675.1 embryonic ectoderm development (Eed)
Immune response
AF316999.1 DNA segment, Chr 11, Lothar Hennighausen 2, (Picalm) expressed
(D11Lgp2e)
NM_010189.1 Fc receptor, IgG, alpha chain transporter (Fcgrt)
BC010229.1 guanylate binding protein 6 (Gbp6)
NM_010259.1 guanylate nucleotide binding protein 1 (Gbp1)
NM_010260.1 guanylate nucleotide binding protein 2 (Gbp2)
NM_008326.1 immunity-related GTPase family, M (Irgm)
NM_008360.1 interleukin 18 (Il18)
NM_008787.1 nucleoporin 85 (Nup85)
Redox homeostasis
NM_025559.1 RIKEN cDNA 1810046J19 gene (1810046J19Rik)
Metabolism
AK002555.1 acetyl-Coenzyme A acyltransferase 2 (Acaa2)
NM_007382.1 acyl-Coenzyme A dehydrogenase, medium chain (Acadm)
NM_007398.1 adenosine deaminase (Ada)
NM_011996.1 alcohol dehydrogenase 4 (class II), pi polypeptide (Adh4)
AF177041.1 aldo-keto reductase family 1, member C12 (Akr1c12)
NM_013778.1 aldo-keto reductase family 1, member C13 (Akr1c13)
AV124668 alpha fetoprotein (Afp)
D85596.1 AMP deaminase 3 (Ampd3)
NM_023850.1 carbohydrate (keratan sulfate Gal-6) sulfotransferase 1 (Chst1)
NM_026819.1 dehydrogenase/reductase (SDR family) member 1 (Dhrs1)
NM_020046.1 dihydroorotate dehydrogenase (Dhodh)
BC027422.1 emopamil binding protein-like (Ebpl)
NM_016772.1 enoyl coenzyme A hydratase 1, peroxisomal (Ech1)
BG069933 expressed sequence C80008 (C80008)
AV307219 galactose mutarotase (Galm)
AK002661.1 glutathione S-transferase kappa 1 (Gstk1)
NM_010357.1 glutathione S-transferase, alpha 4 (Gsta4)
AV018774 hydroxyacyl-Coenzyme A dehydrogenase (Hadh)
BM200015 hydroxysteroid dehydrogenase like 2 (Hsdl2)
AK009478.1 peroxisomal delta3, delta2-enoyl-Coenzyme A isomerase (Peci)
NM_134102.1 phospholipase A1 member A (Pla1a)




BI080136 heterogeneous nuclear ribonucleoprotein U-like 2 (Hnrpul2)
NM_010807.1 MARCKS-like 1 (Marcksl1)
AV366860 membrane bound O-acyltransferase domain containing 1
(Mboat1)
NM_022018.1 niban protein (Niban)
AI647775 Nur77 downstream gene 2 (Ndg2)
X96606.1 ovary testis transcribed (Ott)
BG065719 predicted gene,(EG665081)
BC022950.1 RIKEN cDNA 1600029D21 gene (1600029D21Rik)
BI415578 RIKEN cDNA 2210016F16 gene (2210016F16Rik)
NM_133929.1 RIKEN cDNA E330009J07 gene (E330009J07Rik)
BB493265 small nucleolar RNA, C/D box 22 (Snord22)
NM_011430.1 synuclein, gamma (Sncg)
BB758095 tight junction protein 2 (Tjp2)
AA124553 zinc ﬁnger, AN1-type domain 5 (Zfand5)
Note: These genes were assigned to cluster 3. Genes showing upregulated expression in
necrosis are grouped according to function, and gene symbols are indicated inparentheses.
The bold italic-lettered genes were those upregulated N1.5-fold (pb0.001) in F28-7 cells
compared with those in F28-7-A after treatment with FUdR for 16 h.
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calmodulin-dependent protein kinase ID (Camk1d), caspase recruitment
domain family member 10 (Card10), chloride channel calcium activated 1
(Clca1), integral membrane protein 2B (Itm2b), and serine (or cysteine)
peptidase inhibitor, clade B, member 2 (Serpinb2), with all of the above
being involved in a variety of apoptosis signaling. Interestingly, the diffe-
rentially expressed geneswere also associatedwith the HSP90 chaperone
complex including Hsp110, Dnajb4, and Ahsa1. The FUdR-induced expres-
sionpatterns of apoptosis-related genes, HSP family and related genes, are
shown in Supplementary Data (Supplementary Fig. 1 and Fig. 2).
The genes that are related to cell growth, cytoskeleton organization,
keratinization, plasma membrane repair, mRNA processing, ATP bio-
synthesis, phospholipid biosynthesis, and fatty acid biosynthesis were
upregulated by the FUdR-induced necrosis. In particular, the nephro-
blastomaoverexpressed gene (Nov), keratin 19 (Krt19), thymosin, beta 4,
X chromosome (Tmsb4x), RIKEN cDNA 5730453I16 gene (5730453I16Rik),
myo-inositol 1-phosphate synthase A1 (Isya1), and fatty acid desaturase 2
(Fads2)were upregulatedmore than1.5-fold in F28-7 cells comparedwith
those in F28-7-A in the treatmentwith FUdR.Also, some transcription and
cell adhesion-related genes, such as activating transcription factor 3 (Atf3),
early growth response 1 (Egr1), and selectin, endothelial cell (Sele), had
drastic changes in F28-7 cells during FUdR treatment. The expression
patterns of Nov, Krt19, Tmsb4x, Atf3, Egr1, and Sele are given in Supple-
mentary Data (Supplementary Fig. 3). The vast majority of these genes
have not been previously reported to be affected by FUdR. It should be
noted that although the genes for thymidylate synthase (thedrug's target)
[20], uracil-DNA glycosylase [21], and thymidine kinase [21] were repor-
ted to have signiﬁcant changes in response to FUdR, our microarray
analysis had no changes.
As a follow-up to the microarray, we analyzed the mRNA and
protein expression levels of the identiﬁed apoptosis-related genes,
such as Serpinb2 and Bid, using quantitative real-time PCR (Q-PCR) and
Western blotting. The mRNA expression levels of Serpinb2 and protein
expression levels of BID are listed in Supplementary Data (Supplementary
Figs. 4a and b). The expression patterns of Serpinb2 and BID in Q-PCR and
Western blotting conform with the results of microarray analysis (see
Supplementary Fig. 1). We examined in 1998 the time course of mRNA
expressions of the Jun (c-jun), Fos (c-fos), andMyc (c-myc) byNorthern blot
analysis. In these data, the expression patterns of Jun, Fos, andMycmRNA
showed clear upregulations from 8 to 16 h in F28-7 cells. In contrast, little
upregulation was observed in F28-7-A [12]. The upregulations of Jun and
Fos mRNA detected in the present experiments with the microarray
technique agree with the results of the 1998 Northern blot data. It is




AK009249.1 RIKEN cDNA 2310009E04 gene (2310009E04Rik)
BC020489.1 RIKEN cDNA 2310016F22 gene (2310016F22Rik)
NM_011435.1 superoxide dismutase 3, extracellular (Sod3)
Protein modiﬁcation
BC016526.1 N-myristoyltransferase 1 (Nmt1)
BI525140 plectin 1 (Plec1)
BC016187.1 RIKEN cDNA 2010008E23 gene (2010008E23Rik)
AV002340 RIKEN cDNA 4833442J19 gene (4833442J19Rik)
Protein biosynthesis
NM_026729.1 immature colon carcinoma transcript 1 (Ict1)
AK012225.1 mitchondrial ribosomal protein S7 (Mrps7)
AK002757.1 mitochondrial ribosomal protein L12 (Mrpl12)
BB041267 mitochondrial ribosomal protein L19 (Mrpl19)
NM_011885.1 mitochondrial ribosomal protein S12 (Mrps12)
NM_025440.1 mitochondrial ribosomal protein S16 (Mrps16)
M58566.1 zinc ﬁnger protein 36, C3H type-like 1 (Zfp36l1)
Protein folding
BC025552.1 AHA1, activator of heat shock protein ATPase
homolog 1 (yeast) (Ahsa1)
BC017161.1 DnaJ (Hsp40) homolog, subfamily B, member 4 (Dnajb4)
Protein degradation
AK009033.1 Brca1 associated protein 1 (Bap1)
NM_011189.1 proteasome (prosome, macropain) 28 subunit, alpha (Psme1)
NM_011190.1 proteasome (prosome, macropain) 28 subunit, beta (Psme2)
Signal transduction
BC019379.1 G protein-coupled receptor kinase 5 (Gprk5)
BI645481 guanine nucleotide binding protein, alpha 13 (Gna13)
BC003980.1 protein tyrosine phosphatase, non-receptor type 11 (Ptpn11)
NM_009105.1 Ras suppressor protein 1 (Rsu1)
NM_019662.1 Ras-related associated with diabetes (Rrad)
AF215669.1 regulator of G-protein signaling 3 (RGS3)(C2PA) (Rgs3)
Transcription
AK004254.1 ankyrin repeat domain 46 (Ankrd46)
AI852593 bromodomain PHD ﬁnger transcription factor (Bptf)
NM_007970.1 enhancer of zeste homolog 1 (Drosophila) (Ezh1)
BM232562 feminization 1 homolog b (C. elegans) (Fem1b)
BC016637.1 general transcription factor IIB (Gtf2b)
BC004625.1 neural precursor cell expressed, developmentally
down-regulated gene 8 (Nedd8)
Transport
NM_007899.1 extracellular matrix protein 1 (Ecm1)
BC008525.1 golgi SNAP receptor complex member 2 (Gosr2)
BC011470.1 phosphatidylinositol binding clathrin assembly protein (Picalm)
BC014701.1 potassium voltage-gated channel, shaker-related
subfamily, beta member 1 (Kcnab1)
AK016883.1 RIKEN cDNA 4933425K02 gene (4933425K02Rik)
AF297098.1 six transmembrane epithelial antigen of the prostate 1
(Steap1)
Unknown
NM_007786.1 casein kappa (Csn3)
BC021637.1 CD68 antigen (Cd68)
BE853170 cDNA sequence BC006779 (BC006779)
NM_025779.1 coiled-coil domain containing 109B (Ccdc109b)
NM_007793.1 cystatin B (Cstb)
BE571790 epithelial membrane protein 2 (Emp2)
NM_010500.1 immediate early response 5 (Ier5)
NM_011150.1 lectin, galactoside-binding, soluble, 3 binding protein(Lgals3bp)
NM_024194.1 leucine rich repeat containing 40 (Lrrc40)
AV010467 LIM domain containing 2 (Limd2)
AF263458.1 placenta-speciﬁc 8 (Plac8)
BQ175991 progesterone receptor membrane component 2 (Pgrmc2)
BC009150.1 RAB, member of RAS oncogene family-like 5 (Rabl5)
NM_133231.1 regulatory factor X-associated protein (Rfxap)
BC025602.1 reticulocalbin 3, EF-hand calcium binding domain (Rcn3)
BC026936.1 RIKEN cDNA 1110005A03 gene (1110005A03Rik)
AK015585.1 RIKEN cDNA 2610027L16 gene (2610027L16Rik)
NM_026481.1 RIKEN cDNA 2700055K07 gene (2700055K07Ril)




AY043488.1 selenoprotein M (Selm)
BC022145.1 transmembrane protein 106A (Tmem106a)
BE225838 WD repeats and SOF domain containing 1 (Wdsof1)
Note: These geneswere assigned to cluster 1. Genes showing downregulated expression in
necrosis are grouped according to function, and gene symbols are indicated inparentheses.
The bold italic-letteredgeneswere thosedownregulatedN1.5-fold (pb0.001) inF28-7 cells
compared with those in F28-7-A after treatment with FUdR for 16 h.
13A. Sato et al. / Genomics 92 (2008) 9–17Northern blot analysis in terms of its quantitative power and sensitivity.
Indeed, in the present analysis, theMycmRNA expression did not show a
clear upregulation from 8 to 16 h. These expression patterns obtained by
the microarray data are given in Supplementary Data (Supplementary
Fig. 5). Theseobservations indicate the competencyof themicroarraydata.
Of particular interest in the changes of the expression patterns were
those of a cluster of HSP90 chaperone complex-related genes, parti-
cularly because HSP90 is a current focus of attention as an anticancer-
drug target [19] and is suspected to be involved in TNF-induced necrosis
and apoptosis [16].
FUdR induces release of cytochrome c from mitochondria in apoptosis,
but not in necrosis
A number of apoptosis-related genes involved in mitochondria-de-
pendent apoptosis signaling exhibited differentially expressed patterns
in the observed necrosis and apoptosis. These genes, including Bcl10,
Bid, and Glrx2, showed downregulated expression in the necrosis as
compared to the apoptosis. Therefore, we investigated mitochondrial
events, i.e., changes inmitochondrialmembrane potential and release of
cytochrome c accompanying the treatment with FUdR.
First, we analyzed changes of mitochondrial membrane potential
in F28-7 and F28-7-A cells using the uptake of Rhodamine 123 as a
probe (Fig. 2). At 24 h of the treatment, the pattern changes from the
0-time control were similar in F28-7 and F28-7-A cells. In both cells,
the uptake of Rhodamine 123 was decreased (left-side shift in the dye
content). These observations indicate that the mitochondrial mem-
brane potentials of these cells undergo changes quite similar to each
other during the FUdR treatment.
Next, we investigatedwhether FUdR induces release of cytochrome
c frommitochondria. As shown in Fig. 3, a release of cytochrome c into
cytoplasm and nucleus was detected for F28-7-A but not for F28-7
cells, thus conﬁrming an alteration in the apoptosis-related genes.
Inhibition of HSP90 in F28-7 cells causes a shift fromnecrosis into apoptosis
Microarray analysis also revealed differentially expressed genes in
necrosis and apoptosis among those involved in the HSP90 chaperone
complex. These genes, including Hsp110, Ahsa1, and Dnajb4, are asso-
ciated with stress response and protein folding. However, the mRNA
expression levels of the HSP90 isoforms, HSP90 alpha and HSP90 beta,
showed no signiﬁcant changes in themicroarray analysis. Therefore, we
considered that theHSP90 functionsmay differ between F28-7 and F28-
7-A cells. To investigate the effect of inhibiting the HSP90 functions, we
performedaDNA fragmentation assay in F28-7 andF28-7-Acells treated
with a combination of the HSP90 inhibitor GA and FUdR. As shown in
Fig. 4a, oligonucleosomal DNA fragmentation was induced by this
combination treatment in F28-7 cells. On the other hand, in F28-7-A
cells, such oligonucleosomal DNA fragmentation was induced by treat-
ment both with FUdR alone and with the combination of GA and FUdR
(Fig. 4a). These observations therefore suggest that the HSP90 parti-
cipates in executing the process of necrosis.
We also observedmorphological changes in F28-7 cells treatedwith
the combination of GA and FUdR. FUdR alone induced the cytoplasmic
swelling, a hallmark for necrosis, whereas the combination of GA and
Fig. 2. Change of mitochondrial membrane potential in F28-7 and F28-7-A cells treated with FUdR. F28-7 and F28-7-A cells were treated with 1 μM FUdR for 0, 8, 16, or 24 h, and the
mitochondrial membrane potential was assessed with Rhodamine 123, a membrane-permeant mitochondria-speciﬁc tracer dye, using ﬂow cytometry. Loss of mitochondrial
membrane potential causes release of Rhodamine 123 from mitochondria, resulting in decreased Rodamine 123 intensity. Three independent experiments were performed and the
results shown represent those obtained in one experiment. Two other experiments generated similar results.
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and the formation of apoptotic bodies (Fig. 4b). In the case of F28-7-A,
typical apoptotic phenomena were observed in treatments with FUdR
alone, and with the combination of FUdR and GA (data not shown).
To obtain further evidence for this remarkable phenomenon, we
performed an immunoﬂuorescence study. As shown in Fig. 5, this
study also showed the release of cytochrome c in F28-7 on treatment
with the combination of GA and FUdR. As expected, the cytochrome c
release was not observed in F28-7 cells treated with GA or FUdR alone.
Discussion
In the present study, we investigated the gene expression proﬁles of
FUdR-induced necrosis and apoptosis using cDNA microarray technol-Fig. 3. FUdR induced release of cytochrome c from mitochondria in F28-7-A cells, but
not from F28-7. Immunoﬂuorescence studies in F28-7 and F28-7-A cells. Cells plated on
glass coverslips were treated with 1 μM FUdR for 0 (control) or 16 h. After ﬁxation, the
subcellular distribution of cytochrome c was visualized with anti-cytochrome c
antibodies (green) using a ﬂuorescence microscope. Mitochondria were stained with
MitoTracker Red CMXRos (red). The results shown are those in an experiment out of
three independent experiments (all of them gave similar results).ogy and demonstrated clear differences between these proﬁles. In this
analysis, 215 geneswere identiﬁed asdifferentially expressed in necrosis
and apoptosis induced by FUdR, and the gene expression patterns
differed signiﬁcantly between F28-7 and F28-7-A cells treated for 0, 4, 8,
and 16 h (Fig.1). Among these differentially expressed genes were those
involved in a variety of intracellular signaling pathways, for example,
apoptosis, chromatin modiﬁcation, cytoskeleton organization, and pro-
tein folding (Tables 1 and 2). These 215 genes were classiﬁed into two
clusters according to the gene expression patterns; a cluster of genes
upregulated in the FUdR-induced necrosis compared to those in the
induced apoptosis, and another cluster downregulated in the necrosis
compared to those in the apoptosis. In addition, the microarray analysis
revealed that already in the untreated stage (0-time controls), a number
of genes are differentially expressed between F28-7 and F28-7-A cells.
Therefore, the differences in the gene expression at 0 h may appear to
determine the FUdR-induced necrosis and apoptosis. The differencies in
these sister cells may also be a result of mutation(s), although undis-
covered yet, in the upstream of these genes. Another possible mecha-
nism, however, seems more attractive to us. First, in these differentially
expressed genes, over 90% had similar changing patterns during the
FUdR treatment. Furthermore, some genes that are differentially or
similarly expressed in the untreated stage of F28-7 and F28-7-A cells
show quite different patterns of expression changes during the subse-
quent FUdR treatment. Importantly, our previous work revealed that
newly synthesized proteins are required for the FUdR-induced death of
F28-7 cells. Thus, cycloheximide, an inhibitor of protein biosynthesis,
added to the culture medium at a stage when new protein synthesis
began to start, caused a strong inhibition of the FUdR-induced cell death
[7]. Therefore, the necrosis and apoptosis that occurred seemed to be
regulated by FUdR-inducible genes, requiring newly synthesized pro-
teins. Taken together, we hypothesized that not only the inherent dif-
ferences in the gene expressions of F28-7 and F28-7-A, but also the
dynamic changes in the expressions during the FUdR treatment are
important in determining themodeof the cell death for these sister cells.
We identiﬁed many apoptosis-related genes that showed differ-
ential expressions in necrosis and apoptosis induced by FUdR. These
genes, including the BCL-2 family such as Bcl10, Bid, and Glrx2, are
involved in the mitochondria-dependent apoptosis pathway. Recent
reports have shown that mitochondria play a role in mediating both
apoptosis and necrosis [20–22]. In apoptosis and necrosis, the mito-
chondrial permeability transition (mPT), which leads tomitochondrial
membrane disruption accompanying a total dysfunction, is considered
to be one of the key events [22,23]. Also, release of cytochrome c from
mitochondria is a major event during apoptosis [24–26]. Once relea-
sed into the cytoplasm, cytochrome c is known to form a molecular
Fig. 5. A combination of FUdR and Hsp90 inhibitor GA induces release of cytochrome c
from mitochondria in F28-7 cells. F28-7 cells were treated with vehicle (0.1% DMSO),
1 μM GA alone, 1 μM FUdR alone, or 1 μM FUdR plus 1 μM GA for 16 h. Immunostaining
was performed using anti-cytochrome c antibody (green). Mitochondria were stained
with MitoTracker Red CMXRos (red). The results shown are those of an experiment from
three independent experiments (all of them gave similar results).
Fig. 4. A combination of FUdR and GA induces oligonucleosomal DNA fragmentation and
apoptotic cell morphology in F28-7 cells. (a) Oligonucleosomal DNA fragmentation was
detectedusing2%agarosegel electrophoresis followedbyethidiumbromidestaining. F28-7
and F28-7-A cells were treated with vehicle (0.1% DMSO), 1 μMGA alone,1 μMFUdR alone,
or 1 μM FUdR plus 1 μMGA for 21 h. LaneM shows 123 bp ladder size markers. The results
are representative of four independent experiments. (b) Morphological changes were
observed by Giemsa staining. F28-7 cells were treated with vehicle (0.1% DMSO), 1 μM GA
alone,1 μMFUdR alone, or 1 μMFUdRplus 1 μMGA for 21 h. The results shown are those of
an experiment from three independent experiments (all of them gave similar results).
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to many apoptotic events [24–26]. In many forms of apoptosis, BH3-
domain-containing proteins of the BCL-2 family transduce apoptotic
signals to the mitochondria, and induce cytochrome c release [27]. We
showed that the mitochondrial membrane potential decreases in the
FUdR-induced necrosis and apoptosis in a time-dependent manner
very similar to each other (Fig. 2). However, release of cytochrome c
from mitochondria into the cytoplasm and nucleus was found in the
apoptosis but not in the necrosis (Fig. 3). A recent report suggests that
the nuclear accumulation of cytochrome cmay be directly involved in
the remodeling of chromatin [28]. Therefore, we consider that the
cytochrome c release may be important in the apoptosis induced by
FUdR. Our working hypothesis that the dynamic expression changes
must be the cause of the shift in the cell death mode is in agreement
with this behavioral change of mitochondria.Interestingly, HSP family and related genes showed differential ex-
pression patterns in these cells. These genes, including Hsp110, Dnajb4,
and Ahsa1, are involved in the HSP90 chaperone complex. In particular,
AHA1 is an activator of the HSP90 ATPase activity, which plays a key role
in the regulation of ATP-dependent HSP90 chaperone activity [29–32].
HSP90 is one of the more abundant HSPs, and because it regulates the
stability and function of a unique complement of signal transduction
proteins, this chaperone is involved in a variety of important biological
processes including hormone signaling, cell cycle control, development,
and cell death [13–19]. The HSP90 chaperone machine is driven by ATP
binding and hydrolysis [33–35]. Its activity is regulated by cochaperones
such as AHA1, HSP72, CDC37, p23, CHIP, and immunophilins [36,37].
Therefore, it may be expected that HSP90 ATPase activity differs bet-
ween F28-7 and F28-7-A cells. To investigate the involvement of HSP90
in FUdR-induced necrosis and apoptosis, we used an HSP90 inhibitor,
GA. This naturally occurring ansamycin antibiotic GA binds to a con-
served binding pocket in the amino-terminal domain of HSP90 [38,39],
inhibiting ATP binding and ATP-dependent HSP90 chaperone activity
[33–35]. As shown above, inhibition of HSP90 caused a shift from FUdR-
induced necrosis to apoptosis in F28-7 cells (Figs. 4a and b). Berghe et al.
reported that inhibition of HSP90 function reverts TNF-induced necrosis
to apoptosis [16]. These results suggest that HSP90 is crucial to necrosis.
However, the Ahsa1 gene showed downregulated expressions in F28-7
cells as compared to F28-7-A during the entire period of the FUdR
treatment (Supplementary Fig. 2). Also, the mRNA expression levels of
HSP90 isoforms, HSP90 alpha and HSP90 beta, did not signiﬁcantly
change as revealed by our microarray analysis. Furthermore, we mea-
sured the protein expression levels of the HSP90 isoforms (HSP90 alpha
and HSP90 beta) and AHA1 by proteome analysis using two-dimen-
sional gel electrophoresis and mass spectrometry. The results indicated
that the protein expression levels of HSP90 isoforms were not signi-
ﬁcantly different between F28-7 and F28-7-A cells, in agreement with
the similarity in their gene expression levels. In contrast, however, the
AHA1 protein expression level was found to be downregulated in F28-7
16 A. Sato et al. / Genomics 92 (2008) 9–17cells compared to that in F28-7-A cells (details to be published else-
where). One possibility is that in F28-7 cells AHA1 may be under a
negative feedback control at its transcriptional step by the enhanced
activity of HSP90.
In addition, we demonstrated that a release of cytochrome c from
mitochondria to cytoplasm and nucleus was inducible in F28-7 cells
by a combination of GA and FUdR (Fig. 5). This ﬁnding suggests that
HSP90 may play a role prior to the release of cytochrome c in the
FUdR-induced necrosis and apoptosis. Taken together, these results
permit us to speculate that in F28-7 cells the apoptotic pathway is
blocked by HSP90 and/or HSP90 chaperone complex constructs (such
as AHA1 and HSP110), whereas in F28-7-A cells this block has been
overcome. It appears important to explore further the roles of HSP90
and cochaperone AHA1 in necrosis and apoptosis.
As noted under Results, previous reports from other laboratories
described FUdR-mediated changes in genes for thymidylate synthase
[40], uracil-DNA glycosylase [41], and thymidine kinase [41]. However
in our present survey, we observed no signiﬁcant changes in those
genes. This discrepancy could have resulted from differences in the
cell types and in the analytical methods.
As described above, microarray analysis revealed differently ex-
pressed genes (see bold italic-lettered genes in Tables 1 and 2). Most of
these genes are for the ﬁrst time revealed as differently expressed in
necrosis and apoptosis. Interestingly, some genes were upregulated in
the FUdR-induced necrosis. Participation of these genes in necrosis has
not been reported previously. Furthermore, we analyzed gene expres-
sion changes in apoptotic conditions; namely F28-7 cells treated with a
combinationof FUdR andGA, and F28-7-A cells treatedwith FUdR alone.
The results indicated that genes, involving Serpinb2, Sele, and Egr1, are
downregulated under the apoptotic conditions induced (details to be
published elsewhere). It would be interesting to explore the effect of
knocking down these genes (for example, with siRNAs) to see whether
apoptosis is inducible.
The possible new roles supposedly assignable to HSP90 seem to
warrant further studies. For example, agents other than FUdRmay also
exhibit a similar association with HSP90.
In conclusion, we revealed the gene expression proﬁles of necrosis
and apoptosis induced by FUdR and proposed possible mechanisms
associated with the cell death. Our present work should contribute to
a better understanding of the molecular mechanisms regulating ne-
crosis and apoptosis. Also, we suggest that HSP90 plays a key role in
the regulation of necrosis and apoptosis induced by FUdR.
Materials and methods
Reagents, antibodies, and cell culture
5-Fluoro-2′-deoxyuridine and geldanamycin were obtained from Sigma. Rhodamine
123, 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI), andMitoTracker RedCMXRos
were from Invitrogen. The antibodies anti-cytochrome c and anti-mouse IgG (containing
Alexa 488) were from Calbiochem and Invitrogen, respectively. FUdR was stored as 2 mM
stocks inHPLCgradewaterat−20 °C. GAwas storedas2mMstocks inDMSOat−20 °Cwith
protection from light.
Original-type F28-7 clones ofmousemammary tumor FM3Acells and variant F28-7-A
cells used in the study have been described previously [12]. The cells were cultured in ES
medium (Nissui Pharmaceuticals) supplemented with 2% fetal bovine serum (Gibco) and
0.03% L-glutamine (Wako) in a humidiﬁed atmosphere with 5% CO2 at 37 °C. Under these
conditions, the doubling time of both F28-7 and F28-7-A cells was approximately 12 h.
Microarray analysis and data statistics
For microarray analysis, F28-7 and F28-7-A cells at 2×105 cells/mL were treated with
1 μMFUdR for 0, 4, 8, and 16h. Total RNAwasextractedbyusingQIAshredder spin columns
and an RNeasy Mini kit as described by the manufacturer (QIAGEN). Biotin-labeled cRNA
and the hybridization cocktail were prepared using a One-Cycle Target Labeling kit and
Control Reagents as described in the GeneChip Expression Analysis Manual (Affymetrix).
Brieﬂy, total RNA was converted to double-stranded cDNA using an oligo(dT)24 primer
containing a T7 promoter sequence. The resulting cDNAwas transcribed into biotin-labeled
cRNA using T7 RNA polymerase and biotinylated ribonucleotides. The cRNA product was
puriﬁed, fragmented, and placed in a hybridization cocktail. The hybridization cocktails
were added to GeneChip Mouse Expression Array 430A (Affymetrix) in the GeneChipHybridization Oven 640 under constant rotation at 60 rpm at 45 °C for 16 to 18 h. After the
hybridization, GeneChips were washed and stained with GeneChip Fluidics Station 450
(Affymetrix), andscannedwith aGeneArray 2500 Scanner (Agilent Technologies). Pixel size
was set to 3 μm, ﬁlterwavelength to 570 nm, and scan number to 2. Other parameterswere
set according to the details speciﬁed by Affymetrix for the GeneChip Mouse Expression
Array 430 A. Scanned GeneChip imageswere analyzed using GeneChipOperating Software
(GCOS) ver. 1.4. (Affymetrix). To ensure the reproducibility of the microarray data, three
independent analyses were performed with the GeneChip Mouse Expression Array 430A,
which contains 22,600 probe sets and can be used to analyze the expression level of
∼14,000 known mouse genes. The concentrations of total RNA and biotin-labeled cRNA
were determined by ultraviolet absorbance. The quality and integrity of the total RNA and
fragmented cRNA were conﬁrmed using the Bioanalyzer Experion electrophoresis system
(Bio-Rad).
Rawdatawere analyzedusingArray Assist ver. 5.2. software (Stratagene). Probe sets of
all 24 arrays (three arrays per one time point) were normalized by Affymetrix Microarray
Suite MAS 5.0 (for details see www.affymetrix.com), and genes of absence calls across all
arrays were removed; then probe signal values were transformed to a logarithmic scale.
After this transformation, probe sets were subjected to ANOVA [42,43], setting P values
below 0.001 after application of the Bonferroni correction [44]. Genes with P values
smaller than 0.001were selected for further analysis. Unsupervised hierarchical clustering
using the Pearson correlation with the average linkage rule was performed on the
statistically signiﬁcant probe sets [45,46]. Data are graphically presented as heat maps in
which signal intensity is represented by a color gradient.
Functional classiﬁcation of the genes was based on gene ontology categories
established by the Gene Ontology Consortium (http://www.geneontology.org).
Assessment of mitochondrial membrane potential
To examine changes in the mitochondrial membrane potential, F28-7 and F28-7-A
cells were treated with Rhodamine 123 (ﬁnal concentration 5 μM), a membrane-
permeant mitochondria-speciﬁc tracer dye, for 15 min at 37 °C in a CO2 incubator. Then,
2×105 cells were centrifuged at 250 g, 5 min, 4 °C, and resuspended in phosphate-
buffered saline (PBS). Mitochondrial membrane potential was analyzed by a Beckman
Coulter Epics XL ﬂow cytometry.
Immunoﬂuorescence
F28-7 and F28-7-A cells plated on glass coverslips were treated individually with 1 μM
FUdR. Also, F28-7 cells were treated with vehicle (0.1% DMSO), 1 μM GA alone, 1 μM FUdR
alone, or 1 μMFUdRplus 1 μMGA.Cellswere loadedwithMitoTrackerRedCMXRos (200nM),
a mitochondria selective dye, for 15 min at 37 °C in a CO2 incubator. Cells were rinsed three
times with PBS and then ﬁxed with 4% paraformaldehyde in PBS, for 15 min at room
temperature. After ﬁxation, cells were permeated with 0.2% Triton-X, for 5 min at room
temperature, and rinsed three timeswith PBS. Cellswere then treatedwith blocking solution
(0.5%bovineserumalbumin (BSA) inPBS) for30minat roomtemperatureand incubatedwith
monoclonal anti-cytochrome c antibody diluted to 3.3 μg/mL in blocking solution for 1 h at
room temperature. Excess antibodywas removed bywashing the coverslips three timeswith
PBS for 5min. The secondaryantibody, anti-mouse IgG containingAlexa 488, diluted 1:100 in
blocking solution, was probed for 30 min at room temperature. Staining of the nucleus was
accomplished by incubation with DAPI (1 μg/mL) for 1 min after antibody treatment.
Coverslips were then rinsed three times with PBS for 5 min and mounted onto microscope
slides using PermaFluor Aqueous Mounting Medium (Shandon) and analyzed using an
Olympus BX61 ﬂuorescence microscope equipped with appropriate ﬂuorescence ﬁlters.
Morphological change
To characterize the morphology of F28-7 cells after treatment with vehicle (0.1%
DMSO), 1 μM GA alone, 1 μM FUdR alone, or 1 μM FUdR plus 1 μM GA, cells were ﬁxed
with methanol and stained with Giemsa stain solution (Wako) as described in the
manufacturer's instructions. Cell morphology was observed by an Olympus BX50 light
microscopy.
DNA fragmentation assay
DNA samples for detection of apoptotic oligonucleosomal DNA fragmentation were
prepared as described previously [12]. DNA fragmentationwas detected using 2% agarose
gel electrophoresis followed by ethidium bromide staining.
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